Shedding of ctDNA, radiomics assessment of tumor disease volume (TDV), and concordance of mutations (mut) in synchronous liquid and tumor biopsies in metastatic breast cancer (MBC).

被引：0

作者：

Papakonstantinou, Andri

Gonzalez-Medina, Alberto

Matito, Judit

Ligero, Marta

Ruiz-Pace, Fiorella

Sunol, Anna

Rivero, Joaquin

Fasani, Roberta

Cruellas, Mara

Peg, Vicente

Borrell, Maria

Pimentel, Isabel

Munoz, Santiago Escriva De Romani

Gelpi, Judith Balmana

Nuciforo, Paolo

Dienstmann, Rodrigo

Saura, Cristina

Perez-Lopez, Raquel

Oliveira, Mafalda

Vivancos, Ana

机构：

[1] Karolinska Inst & Breast Canc Grp, Vall Hebron Inst Oncol VHIO, Dept Oncol Pathol, Barcelona, Spain

[2] Vall Hebron Inst Oncol VHIO, Canc Genom Grp, Barcelona, Spain

[3] Vall Hebron Inst Oncol VHIO, Radi Grp, Barcelona, Spain

[4] Vall Hebron Inst Oncol VHIO, Oncol Data Sci ODysSey Grp, Barcelona, Spain

[5] Vall Hebron Inst Oncol VHIO, Breast Canc Grp, Barcelona, Spain

[6] Vall dHebron Univ Hosp, Breast Canc Ctr, Breast Surg Unit, Barcelona, Spain

[7] Vall Hebron Inst Oncol VHIO, Mol Oncol Grp, Barcelona, Spain

[8] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept & Breast Canc Grp, Barcelona, Spain

[9] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain

[10] Vall dHebron Inst Oncol, Clin Canc Genet & Breast Canc Grp, Barcelona, Spain

[11] Vall Hebron Inst Oncol, Barcelona, Spain

[12] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1086

引用

页数：1

共 50 条

[21] Efficacy of palbociclib plus fulvestrant (P plus F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA).
Turner, Nicholas C.
Jiang, Yuqiu
O'Leary, Ben
Hrebien, Sarah
Cristofanilli, Massimo
Andre, Fabrice
Loibl, Sibylle
English, Patricia A.
Zhang, Ke
Randolph, Sophia
Bartlett, Cynthia Huang
Koehler, Maria
Loi, Sherene
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[22] Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry
Stefanovic, Stefan
Wirtz, Ralph
Deutsch, Thomas M.
Hartkopf, Andreas
Sinn, Peter
Varga, Zsuzsanna
Sobottka, Bettina
Sotiris, Lakis
Taran, Florin-Andrei
Domschke, Christoph
Hennigs, Andre
Brucker, Sara Y.
Sohn, Christof
Schuetz, Florian
Schneeweiss, Andreas
Wallwiener, Markus
ONCOTARGET, 2017, 8 (31) : 51416 - 51428
[23] Assessment of circulating tumor cells (CTC) by RT/PCR as a surrogate marker for PFS in metastatic breast cancer (MBC)
Saber, M. M.
Bahnasy, A. A.
EI-Zawahry, H. M.
Allahloubi, N. M.
El-Moetii, M. A.
Abd El Fatah, R. M.
Aid, S.
Ghareeb, M.
CANCER RESEARCH, 2013, 73
[24] Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)
Gerratana, Lorenzo
Zhang, Qiang
Shah, Ami Naimish
Davis, Andrew Adam
Zhang, Youbin
Wehbe, Firas
Qiang, Wenan
Flaum, Lisa
Finkelman, Brian Steven
Gradishar, William John
Platanias, Leonidas C.
Behdad, Amir
Cristofanilli, Massimo
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 145
[25] RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter Study.
Bachet, Jean-Baptiste
Bouche, Olivier
Taieb, Julien
Dubreuil, Olivier
Garcia, Marie-Line
Meurisse, Aurelia
Gornet, Jean-Marc
Artru, Pascal
Louafi, Samy
Soularue, Emilie
Baumgaertner, Isabelle
Coriat, Romain
Tougeron, David
Lecomte, Thierry
Mary, Florence
Marthey, Lysiane
Blons, Helene
Taly, Valerie
Bonnetain, Franck
Laurent-Puig, Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[26] Circulating tumor DNA (ctDNA) mutation (mut) profile in relation to paboclicib (pal) efficacy in hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC)
Xi, Jing
Bagegni, Nusayba
Ademuyiwa, Foluso
Frith, Ashley
Suresh, Rama
Roshal, Anna
Rigden, Caron
Hernandez-Aya, Leonel
Peterson, Lindsay
Opyrchal, Mateusz
Clifton, Katherine
Weilbaecher, Katherine
Bose, Ron
Ma, Cynthia
CANCER RESEARCH, 2021, 81 (04)
[27] Correlating total tumor volume on CT-Scan and liquid biopsy ctDNA in 1017 patients with metastatic cancer: A novel study
Belkouchi, Y.
Dawi, L.
Lawrance, L.
Ammari, S.
Vasseur, D.
Wirth, F.
Gautier, O.
Cournede, P-H.
Hadchiti, J.
David, C.
Bidault, F.
Balleyguier, C.
Kind, M.
Talbot, H.
Italiano, A.
Lassau, N.
ANNALS OF ONCOLOGY, 2023, 34 : S237 - S237
[28] Detection, dynamic monitoring, and resistance mechanism exploration of genomic alterations in circulating cell free tumor DNA (ctDNA) in Chinese metastatic breast cancer (mBC).
Li, Huiping
Yu, Jianjun
Liu, Xiao-Ran
Wang, Amy
Zhao, Zhixin
Cheung, Tak
Shi, Wei-Jie
Zhang, Yue
Zhang, Phoebe
Tan, Meng-Yao
Du, Peter
Kong, Wei-yao
Liu, Ya-Xin
Zhang, Jia-yang
Yan, Ying
Jia, Shidong
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] Investigating oncogenic signaling pathways in inflammatory metastatic breast cancer (MBC) though circulating tumor DNA (ctDNA) next-generation sequencing (NGS)
Gerratana, Lorenzo
Davis, Andrew A.
Mina, Marco
Jacob, Saya L.
Zhang, Qiang
Shah, Ami N.
D'Amico, Paolo
Katam, Neelima
Wehbe, Firas
Vagia, Elena
Flaum, Lisa
Platanias, Leonidas
Behdad, Amir
Puglisi, Fabio
Gradishar, William J.
Ciriello, Giovanni
Cristofanilli, Massimo
CANCER RESEARCH, 2021, 81 (04)
[30] ASO Author Reflections: Advancing Circulating Tumor Cells as Liquid Biopsies to Efficiently Target Metastatic Breast Cancer
Ring, Alexander
Lang, Julie E.
ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (05) : 2895 - 2896

← 1 2 3 4 5 →